SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

Drug Requested: Aliqopa® (copanlisib) IV (J9999/C9399) (Medical)

MEMBER & PRESCRIBER IN	FORMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Author	ization may be delayed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Veight: Date:	
Dosage will be approved for 60m and 15 of a 28 day cycle.	ng administered as an intravenous infusion on Days 1, 8,
	ox, the timeframe does not jeopardize the life or health of the member imum function and would not subject the member to severe pain.
	elow all that apply. All criteria must be met for approval. To tion, including lab results, diagnostics, and/or chart notes, must be
☐ Member is age 18 years or older	
AND	
☐ Prescribing physician is an oncolo	ogist or hematologist

(Continued on next page)

A	N	D
	1	_

Member has a diagnosis of relapsed follicular lymphoma, defined as having received at least two prior
systemic therapies

Medication being provided by (check box below that applies):		
□ Location/site of drug administration:		
NPI or DEA # of administering location:		
<u>OR</u>		
□ Specialty Pharmacy - PropriumRx		

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *